Question explored with the scientific record
Should I get a Shingrix vaccine at 55
At 55, Shingrix cuts your shingles risk by about 97% for at least 8 years, but you will likely feel it: most people get injection-site reactions that last a day or two, and a small autoimmune flare risk exists.
The ZOE-50 trial, funded by GSK, found 97.2% efficacy against shingles in adults 50 and older over 3.2 years [1][3]. Long-term follow-up showed protection stayed at 84.1% through year 8 [1]. A real-world Medicare study found lower effectiveness, about 70% after two doses, which is still substantial [1]. The number needed to vaccinate to prevent one shingles case is about 10 [2].
The safety profile is dominated by short-term reactions. About 80% of people get injection-site pain or swelling, and about 15% get systemic symptoms like fever or headache, typically lasting 1-3 days [4][6]. A 2025 VAERS analysis found a signal for autoimmune disease flares, with an overall reporting odds ratio of 3.0, highest for lupus (7.5) and multiple sclerosis (5.6) [5]. Most flares occurred within 3 days of vaccination [5]. A separate study found about 3 excess Guillain-Barré syndrome cases per million doses [1].
| Outcome | Without vaccine | With Shingrix (two doses) |
|---|---|---|
| Shingles cases per 1,000 people over ~3 years | About 9 per year [8] | About 0.3 per year [8] |
| Postherpetic neuralgia cases | About 15% of shingles cases [7] | Reduced by 91% [3] |
| Short-term injection-site reaction | - | About 80% of recipients [6] |
| Autoimmune flare signal (VAERS) | - | ROR 3.0, highest in SLE [5] |
The evidence is from manufacturer-funded trials with a placebo control, which is the right design. The long-term safety data beyond 10 years does not exist. At 55, your shingles risk is lower than at 70, but the vaccine works very well in your age group. The trade-off is between a painful but usually self-limited disease and a vaccine that causes frequent short-term discomfort and carries a small but real risk of triggering an autoimmune reaction.
My call: the vaccine is highly effective and the short-term side effects are predictable, but the autoimmune signal, though small, is real and worth discussing with a doctor who knows your personal and family history of autoimmune conditions. Confidence: moderate.
Sources used 8
-
Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines
This narrative review finds real-world vaccine effectiveness of about 46% for live zoster vaccine and about 85% for recombinant zoster vaccine, with mostly local reactions and a small Guillain-Barré syndrome signal to monitor.
DOI: 10.3390/v14122667 -
Cost-effectiveness of an Adjuvanted Recombinant Zoster Vaccine in older adults in the United States
A Markov-based cost-effectiveness analysis demonstrates that the adjuvanted recombinant zoster vaccine (RZV) is cost-effective versus no vaccination and cost-saving versus ZVL for US adults aged 60+, using a 1-million-person lifetime cohort and US population data.
DOI: 10.1016/j.vaccine.2018.07.005 -
What is Different about Recombinant Herpes Zoster Vaccine?
This narrative review concludes that recombinant zoster vaccine is more effective and longer-lasting than live zoster vaccine, has an acceptable safety profile, and is recommended for adults aged ≥50 years and severely immunocompromised adults aged ≥18 years.
DOI: 10.3904/kjm.2024.99.4.180 -
Healthy ageing: Herpes zoster infection and the role of zoster vaccination
This narrative review concludes that adjuvanted recombinant zoster vaccine prevents herpes zoster and postherpetic neuralgia, has a reassuring safety profile, and is a key action for healthy ageing.
DOI: 10.1038/s41541-023-00757-0 -
Risk of autoimmune disease flares after recombinant zoster vaccine: A vaccine safety analysis based on the Vaccine Adverse Event Reporting System database
This VAERS-based study quantified the risk of autoimmune-disease flares after recombinant zoster vaccination across five diseases (RA, MS, IBD, psoriasis, SLE), finding a positive safety signal with higher risk in SLE and most flares occurring within 3 days, highlighting the nee…
DOI: 10.1080/21645515.2025.2590257 -
Safety profile and medium- to long-term protection of the Recombinant Zoster Vaccine (RZV) in a cohort of high-risk patients: real-world data from a General Hospital in Southern Italy, 2021–2025
A prospective real-world study in a Southern Italian hospital evaluated the safety, disease-flare potential, and medium-to-long-term protection against herpes zoster after Recombinant Zoster Vaccine (RZV) in a medically diverse, vulnerable adult population, finding acceptable sa…
DOI: 10.1080/14760584.2025.2589216 -
Advances in the understanding of the pathogenesis and epidemiology of herpes zoster
A comprehensive review of varicella-zoster virus biology, latency and reactivation, and the epidemiology of herpes zoster, summarizing risk factors, immune mechanisms, complications (notably postherpetic neuralgia), viral genotyping, and vaccination implications across temperate…
DOI: 10.1016/S1386-6532(10)70002-0 -
Efficacy of varicella (VZV) vaccination: an update for the clinician
Varicella vaccines dramatically reduce varicella incidence and severe disease, with newer zoster vaccines offering strong, age-independent protection while research into ORF7 and neuroattenuated strategies points toward next-generation vaccines.
DOI: 10.1177/2051013616655980